These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36961395)

  • 21. High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.
    Dong Y; Zheng M; Wang X; Yu C; Qin T; Shen X
    BMC Cancer; 2023 Nov; 23(1):1097. PubMed ID: 37950153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer.
    Xie X; Liang H; Jiangting W; Wang Y; Ma X; Tan Z; Cheng L; Luo Z; Wang T
    Front Mol Biosci; 2023; 10():1198557. PubMed ID: 37484531
    [No Abstract]   [Full Text] [Related]  

  • 23. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The circadian rhythm key gene
    Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
    Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
    Shima K; Nosho K; Baba Y; Cantor M; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Int J Cancer; 2011 Mar; 128(5):1080-94. PubMed ID: 20473920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and validation of EMT-immune-related prognostic biomarkers CDKN2A, CMTM8 and ILK in colon cancer.
    Kang N; Xie X; Zhou X; Wang Y; Chen S; Qi R; Liu T; Jiang H
    BMC Gastroenterol; 2022 Apr; 22(1):190. PubMed ID: 35429970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-Hydroxyphenylpyruvate Dioxygenase-Like predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.
    Li H; Liu J; Wang S; Xu Y; Tang Q; Ying G
    Aging (Albany NY); 2024 Mar; 16(5):4327-4347. PubMed ID: 38451188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allograft inflammatory factor 1 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer.
    Liu X; Zhang D; Hu J; Xu S; Xu C; Shen Y
    Aging (Albany NY); 2023 Apr; 15(7):2582-2609. PubMed ID: 37014322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A senescence-based prognostic gene signature for colorectal cancer and identification of the role of SPP1-positive macrophages in tumor senescence.
    Yu S; Chen M; Xu L; Mao E; Sun S
    Front Immunol; 2023; 14():1175490. PubMed ID: 37090726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
    Luo JP; Wang J; Huang JH
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34405225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
    Liu C; Zhang W; Zhou X; Liu L
    Front Immunol; 2022; 13():983490. PubMed ID: 36618420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive assessment of cellular senescence in the tumor microenvironment.
    Wang X; Ma L; Pei X; Wang H; Tang X; Pei JF; Ding YN; Qu S; Wei ZY; Wang HY; Wang X; Wei GH; Liu DP; Chen HZ
    Brief Bioinform; 2022 May; 23(3):. PubMed ID: 35419596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response.
    Li Z; Li Y; Tian Y; Li N; Shen L; Zhao Y
    Front Immunol; 2023; 14():1170539. PubMed ID: 37275863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
    Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and Predict Poor Clinical Outcome.
    Soltan MA; Alhanshani AA; Shati AA; Alqahtani YA; Alshaya DS; Alharthi J; Altalhi SA; Fayad E; Zaki MSA; Eid RA
    Biomedicines; 2023 Aug; 11(8):. PubMed ID: 37626750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A.
    O'Hara SP; Splinter PL; Trussoni CE; Pisarello MJ; Loarca L; Splinter NS; Schutte BF; LaRusso NF
    J Biol Chem; 2017 Mar; 292(12):4833-4846. PubMed ID: 28184004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker.
    Huang Y; Zhou X; Li X; Huang D; Fang Z; Ding R
    Oncol Res; 2023; 31(2):193-205. PubMed ID: 37304239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The
    Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
    Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.